Tuesday, 6 October 2026
Qdenga arrives in Australia, Chronic care phone items, GLP-1 fasting concerns
- 01
Qdenga dengue vaccine becomes available in Australia
Qdenga is available in Australia for the first time, with GPs able to order the dengue vaccine for their practices. ATAGI recommends the live-attenuated tetravalent vaccine for people aged four years and over who have a confirmed or likely dengue history and will travel to endemic areas, and for those without prior dengue who plan prolonged or repeated visits. For short-term travellers without a dengue history, ATAGI says vaccination can be considered following an individual risk–benefit assessment. The vaccine is given as two 0.5 mL injections at least 12 weeks apart, with both doses considered essential to maximise the level and duration of protection; evidence is not yet sufficient to recommend boosters. Nearly all notified Australian cases are acquired overseas, with notifications reaching a record 2381 in 2024 before falling to 1863 in 2025.
via RACGP newsGP · also covered by The Medical Republic
- 02
Four chronic condition phone items join November MBS changes
Four new MBS phone attendance items for chronic condition management will take effect on 1 November. Items 92033, 92034, 92063 and 92064 will cover attendances by a GP or prescribed medical practitioner to prepare or review a patient’s chronic condition management plan. They follow the 2025 replacement of GP management plans, team care arrangements and reviews with a single GP chronic condition management plan. A Medicare Healthy Kids Check for three-year-olds will also commence in November, using existing time-tiered health assessment items 701–07 for GPs and 224–227 for other prescribed medical practitioners.
via RACGP newsGP
- 03
Anaesthetists question standard fasting for patients taking GLP-1s
Standard pre-surgery fasting may be inadequate for patients taking GLP-1 medicines and other weight-loss peptides, Australian anaesthetists have warned. The concern applies to patients using these medicines before surgery. The source gives limited detail about the evidence or any proposed changes to perioperative management.
- 04
VAX-31 met all objectives in pivotal pneumococcal vaccine trial
VAX-31 met all primary efficacy objectives in the first of three phase 3 studies among adults aged 50 years or older. The experimental pneumococcal vaccine matched the effectiveness of Pfizer’s Prevnar 20 and Merck’s Capvaxive against 28 bacterial strains and was superior against three unique strains, although it was inferior to Capvaxive on two strains under a more rigorous statistical threshold. Vaxcyte said the vaccine was well tolerated, with a safety profile similar to both comparators and mostly mild-to-moderate adverse events that generally resolved within two days. The vaccine is designed to cover more than 30 strains, and Vaxcyte plans to report two further late-stage trial results next year before seeking approval if those data are positive.
via BioPharma Dive
- 05
Diabetes screening found similar progression regardless of family history
Population screening of 219,951 children in Germany confirmed early-stage type 1 diabetes in 590 children at the initial screen. Across the first and second screens, 619 children had stage 1 or 2 disease, with cumulative progression to clinical diabetes reaching 36.2% at five years and no significant difference by first-degree family history. The researchers said the findings suggested screening could extend beyond genetically selected populations. Separately, an Australian study of 5202 people diagnosed before age 16 found that onset before age seven was associated with lower risks of cardiac, kidney, severe retinal, lower-limb vascular and peripheral nerve complications over the following two decades than onset at ages 13–16.
- 06
Senate inquiry calls for national youth justice overhaul
A Senate inquiry has called for an overhaul of Australia’s youth justice system after finding compelling evidence of the need for change. Its final report recommended national minimum standards, a National Child and Community Safety Taskforce, a public education campaign and a further inquiry into factors contributing to youth incarceration. The committee said the system costs Australia more than $1.1 billion annually, damages children and families, fails to address offending and undermines community safety. It also noted the benefits of supporting at-risk children before they encounter the justice system and the overrepresentation of Aboriginal and Torres Strait Islander children in detention. The RACGP backed a health-first approach, including earlier responses to health and developmental needs, culturally connected care and raising the age of criminal responsibility to 14.
via RACGP newsGP
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.